KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Change in Taxes (2016 - 2025)

Biogen (BIIB) has 12 years of Change in Taxes data on record, last reported at -$194.0 million in Q4 2025.

  • For Q4 2025, Change in Taxes fell 1282.93% year-over-year to -$194.0 million; the TTM value through Dec 2025 reached -$958.1 million, down 1320.51%, while the annual FY2025 figure was -$958.1 million, 1320.51% down from the prior year.
  • Change in Taxes reached -$194.0 million in Q4 2025 per BIIB's latest filing, up from -$229.4 million in the prior quarter.
  • Across five years, Change in Taxes topped out at $106.7 million in Q2 2021 and bottomed at -$603.8 million in Q2 2025.
  • Average Change in Taxes over 5 years is -$54.5 million, with a median of -$17.6 million recorded in 2021.
  • The widest YoY moves for Change in Taxes: up 3240.91% in 2025, down 10878.18% in 2025.
  • A 5-year view of Change in Taxes shows it stood at -$29.7 million in 2021, then tumbled by 41.75% to -$42.1 million in 2022, then crashed by 337.53% to -$184.2 million in 2023, then surged by 108.9% to $16.4 million in 2024, then plummeted by 1282.93% to -$194.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Taxes were -$194.0 million in Q4 2025, -$229.4 million in Q3 2025, and -$603.8 million in Q2 2025.